Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.
1 - 20 . (canceled)
21 . A method of treating pancreatic cancer in a human patient after disease progression following gemcitabine-based therapy, the method comprising intravenously administering, in an administration cycle that repeats every two weeks, an effective amount of each of: (1) liposomal irinotecan and (2) 5-fluorouracil (5-FU), wherein:
(a) the liposomal irinotecan is administered to the patient on day 1 of each cycle in an amount of irinotecan moiety that provides the equivalent of between 50 mg/m 2 to 70 mg/m 2 of irinotecan free base, and
(b) no antineoplastic agent is administered for treatment of the pancreatic cancer other than liposomal irinotecan and 5-FU.
22 . The method of claim 21 , wherein the pancreatic cancer is metastatic pancreatic adenocarcinoma.
23 . The method of claim 22 , further comprising administering an effective amount of leucovorin.
24 . The method of claim 23 , wherein the liposomal irinotecan administration is followed by intravenous administration of the leucovorin, followed by intravenous administration of the 5-fluorouracil and each infusion is initiated on the first day of the cycle.
25 . The method of claim 24 , wherein the liposomal irinotecan is administered on day 1 of each cycle as an intravenous irinotecan sucrose octasulfate salt liposome injection.
26 . The method of claim 25 , wherein the 5-FU is administered as an intravenous infusion over 46 hours.
27 . The method of claim 26 , wherein the leucovorin is administered as an intravenous infusion over 30 minutes.
28 . The method of claim 27 , wherein the leucovorin is administered at a dose of 200 mg/m 2 .
29 . The method of claim 21 , wherein the liposomal irinotecan comprises one or more lipids and the molar ratio of the irinotecan to the one or more lipids in totality is about 0.02 to about 5.
30 . The method of claim 21 , wherein the liposomal irinotecan comprises one or more lipids and the moles of irinotecan per mole of total liposomal lipids is from about 0.15 to about 1.5.
31 . The method of claim 21 , wherein the liposomal irinotecan comprises one or more lipids and the liposomal irinotecan comprises about 1.25 to about 2.42 moles of irinotecan per gram of lipid.
32 . The method of claim 21 , wherein the liposomal irinotecan comprises one or more lipids and wherein the ratio of millimoles of irinotecan per gram of total liposomal lipids is about 0.8 mmol irinotecan per 1 gram of total liposomal lipids.
33 . The method of claim 21 , wherein the liposomal irinotecan comprises one or more lipids and the molar ratio of the irinotecan to the one or more lipids in totality is about 0.2.
34 . A method of treating pancreatic cancer in a human patient after disease progression following gemcitabine-based therapy, the method comprising intravenously administering to the patient, in an administration cycle that repeats every 2 weeks, an effective amount of each of: (1) liposomal irinotecan and (2) 5-fluorouracil (5-FU), wherein:
(a) liposomal irinotecan is administered to patients homozygous for the UGT1A1*28 allele on day 1 of cycle 1 in an amount of irinotecan moiety that provides the equivalent of 50 mg/m 2 of irinotecan free base and on day 1 of each subsequent cycle in an amount of irinotecan moiety that provides the equivalent of between 50 mg/m 2 to 70 mg/m 2 of irinotecan free base;
(b) 5-FU is administered at a dose of 2400 mg/m 2 ; and
(c) no antineoplastic agent is administered for treatment of the pancreatic cancer other than liposomal irinotecan and 5-FU.
35 . The method of claim 34 , wherein the pancreatic cancer is metastatic pancreatic adenocarcinoma.
36 . The method of claim 35 , further comprising administering an effective amount of leucovorin.
37 . The method of claim 36 , wherein the liposomal irinotecan administration is followed by intravenous administration of the leucovorin, followed by intravenous administration of the 5-fluorouracil and each infusion is initiated on the first day of the cycle.
38 . The method of claim 37 , wherein the liposomal irinotecan is administered on day 1 of each cycle as an intravenous irinotecan sucrose octasulfate salt liposome injection.
39 . The method of claim 38 , wherein the 5-FU is administered as an intravenous infusion over 46 hours.
40 . The method of claim 39 , wherein the leucovorin is administered as an intravenous infusion over 30 minutes.
41 . The method of claim 40 , wherein the leucovorin is administered at a dose of 200 mg/m 2 .
42 . The method of claim 34 , wherein the liposomal irinotecan comprises one or more lipids and the molar ratio of the irinotecan to the one or more lipids in totality is about 0.02 to about 5.
43 . The method of claim 34 , wherein the liposomal irinotecan comprises one or more lipids and the moles of irinotecan per mole of total liposomal lipids is from about 0.15 to about 1.5.
44 . The method of claim 34 , wherein the liposomal irinotecan comprises one or more lipids and the liposomal irinotecan comprises about 1.25 to about 2.42 moles of irinotecan per gram of lipid.
45 . The method of claim 34 , wherein the liposomal irinotecan comprises one or more lipids and wherein the ratio of millimoles of irinotecan per gram of total liposomal lipids is about 0.8 mmol irinotecan per 1 gram of total liposomal lipids.
46 . The method of claim 34 , wherein the liposomal irinotecan comprises one or more lipids and the molar ratio of the irinotecan to the one or more lipids in totality is about 0.2.